Clidet 323 (Pty) Ltd and MCG Industries (Pty) Ltd (59/LM/Oct01) [2001] ZACT 47 (3 December 2001)

60 Reportability
Competition Law

Brief Summary

Competition Law — Merger Approval — Merger between Clidet 323 (Pty) Ltd and MCG Industries (Pty) Ltd — Competition Tribunal approves merger unconditionally — No product overlap between merging parties — Merger expected to create positive empowerment opportunities through black economic empowerment company WIP — Tribunal concludes merger will not substantially lessen or prevent competition in any market.

COMPETITION TRIBUNAL 
REPUBLIC OF SOUTH AFRICA
        Case No: 59/LM/Oct01
In the large merger between: 
Clidet 323 (Pty) Ltd
and
MCG Industries (Pty) Ltd
_______________________________________________________________________
Reasons for Decision
_______________________________________________________________________
APPROVAL
On 28 November 2001 the Competition Tribunal issued a Merger Clearance Certificate
approving   the   merger   between   Clidet   323   (Pty)   Ltd   and   MCG   Industries   (Pty)   Ltd  
without   conditions   in   terms   of   section   16(2)(a).   The   reasons   for   the   approval   of   the  
merger appear below.
The Parties
1. The Primary Acquiring firm is Clidet 323 (Pty) Ltd (“Clidet”), a special purpose  
vehicle   set   up   to   house   the   investment   of   the   current   management   of   MCG  
Industries (Pty) Ltd (“MCG”), RMB Ventures Two (Pty) Ltd (“RMBV2”) and  
WIP Capital (Pty) Ltd (“WIP”) in MCG. Clidet is therefore the vehicle through  
which   Rand   Merchant   Bank   (“RMB”)   and   WIP   will   acquire   the   business   of  
MCG.
2. RMBV2   is   a   subsidiary   of   First   RandBank   Holdings   Limited   and   ultimately  
controlled   by  FirstRand  Limited  (“FirstRand”).   It  holds  several   of  FirstRand’s  
private equity investments. FirstRand’s principal activities are retail and merchant  
banking, private equity investing, insurance and asset management.
3. WIP   is   a   black   empowerment   company   which   provides   specialized   financial  
services   including   corporate   finance   advisory   services,   debt   products   advisory  
services,   derivative   structuring,   asset   management,   equity   and   bond   broking,  
treasury outsourcing and private equity fund management. WIP and RMBV2 each  
hold 50% in WIP Private Equity (Pty) Ltd (“WIP P/E”). Another WIP subsidiary

is WIP Capital One (Pty) Ltd (“WCO”), in which WIP  holds 100% of the issued  
share capital. 
4. The Primary Target firm is MCG Industries (Pty) Ltd and Metal Closures Group  
South Africa Limited (jointly referred to as “MCG”), who carry on business as  
manufacturers  of plastic and aluminium  closures and injection moulded crates,  
containers  and chairs (“the MCG  business”). MCG  is ultimately  controlled  by  
Wassall, a large UK conglomerate, and has been so since 1990, when it de­listed  
MCG from the Johannesburg Stock Exchange.
5. MCG manufactures plastic closures (utilised  in the pharmaceutical,  soft drinks  
and   mineral   water   industries);   aluminium   closures   (used   for   sealing  
pharmaceutical  products, soft drinks, liquor  and specific  grocery items);  crates  
(designed for different industries, such as,  inter alia,  the wine, soft drink, beer and  
dairy industries); containers or materials handling (utilized for fruit storage and  
distribution, agricultural, bread trays, chicken crates); chairs (ranging from heavy­
duty chairs to stadium seats).
6. MCG   will   obviously   supply   these   products   to   the   above   industries,   its     main  
customers being SA Breweries, Distell, Stellenbosch Vineyards and Coca­Cola  
bottlers, such as A.B.I.
Rationale for the Merger
7. The underlying rationale for the merger is that Zumtobel A.G., an Austrian­based  
lighting   group,   acquired   Wassall   in   April   2000.   MCG   is   being   sold   to   Clidet  
since, as a packaging company,   it is a non­core business entity to Zumtobel’s  
lighting business. 
The merger transaction 
8. This   is a private equity investment whereby RMB and WIP are acquiring the  
business   of   MCG   through   Clidet,   the   special   purpose   vehicle.   This   is   being  
effected in two stages:
a. MCG will sell its manufacturing business of plastic and aluminium   and  
injection   moulded   crates,   containers   and   chairs   to   RMB   as   a   going  
concern.

concern. 
b. RMB will immediately on­sell the MCG business as a going concern to  
Clidet 323. 
9. The consideration payable in respect of both sales will be identical.

10. Post­merger, the business will be owned and conducted by Clidet 323, who will  
be   owned   by   management,   WIP   and   FirstRand.   RMB   will   provide   banking  
facilities to MCG which will be priced on an arm’s length basis and will oversee  
the performance of the investment in MCG:
Post Merger Structure
EVALUATING THE MERGER
11. Based   on   the   information   supplied   to   us   by   the   parties,   there   is   no   product  
overlap   between   the   products/services   provided   by   the   merging   parties .   The 
parties assure that neither WIP nor RMB have any subsidiaries or other private  
equity investments in any packaging, metal closures or other similar business to  
that   carried   out   by   MCG,  nor   do  they   have   any  holdings   in   any   of  MCG’s  
competitors.
Share incentive  
Trust 
Management  RMBV2 WIP 
     25%    34.9%%
5% 34.9%
CLIDET 
100%
MCG BUSINESS

Public Interest Considerations
12. The merger will have no negative effect on employment. The parties maintain  
that  positive  empowerment   opportunities   will  arise   from  the   merger   because  
WIP is a black economic empowerment company and there are opportunities for  
such appointments to the board of Clidet. WIP and WIP P/E will collectively be  
entitled to appoint 5 of the 11 directors to the Board.
CONCLUSION
The Tribunal accordingly endorses the Commission’s view that this merger will not  
substantially lessen or prevent competition in any market and therefore approves it  
unconditionally.
_____________ 3 December 2001
D.H. Lewis Date
  
Concurring: N. Manoim, P. Maponya